Company: PFSA
Filing Date: 2025-08-21
Form Type: S-1/A
Source: 0001213900-25-079401
Chunk: 22

Company: Profusa, Inc.
Filing Date: 2025-08-21
Form: S-1/A
Chunk 22
---
. Since inception, we have devoted substantially all of our financial resources to developing our products and related services. We have financed our operations primarily through the issuance of equity and debt securities. We have incurred significant losses. The amount of our future net losses will depend, in part, on regulatory approval, commercialization and on -goingdevelopment of our products and related services, the rate of our future expenditures and our ability to obtain funding through the issuance of our securities, strategic collaborations or grants. We expect to 11 continue to incur significant losses for several years as we continue to commercialize our Lumee Oxygen and Glucose Platform and seek to develop and commercialize new products and services. We anticipate that our expenses will increase substantially if and as we: •continue to build our sales, marketing and distribution infrastructure to commercialize our products and services; •continue to develop our products and services; •continue to conduct clinical studies; •seek to identify, assess, acquire, license and/or develop other products and services and subsequent generations of our current products and services; •seek to maintain, protect and expand our intellectual property portfolio; •seek to attract and retain skilled personnel; and •support our operations as a public company. Our ability to generate future revenue from product and service sales depends heavily on our success in many areas, including, but not limited to: •launching and commercializing current and future products and services; •obtaining and maintaining marketing authorization with respect to each of our products and maintaining regulatory compliance throughout relevant jurisdictions; •maintaining clinical and economical value for end -usersand customers in changing environments; •addressing any competing technological and market developments; •negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter; •establishing and maintaining manufacturing facilities; •establishing and maintaining distribution relationships with third -partiesthat can provide adequate (in amount and quality) infrastructure to support market demand for our products; and •maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know -how. We have incurred significant losses in the past and will likely incur losses in the future. We have incurred significant operating losses in the past. We have financed our operations primarily through the issuance of equity and debt. We have devoted substantial resources to: •research and development relating to our Lumee Oxygen and Glucose Platform; •clinical studies for our Lumee Oxygen and Glucose Platform; •execution and maintenance of our intellectual property portfolio; •expenses associated with the commercialization of our